{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T07:27:44Z","timestamp":1789802864987,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T00:00:00Z","timestamp":1559692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.rmed.2019.06.001","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T11:17:04Z","timestamp":1559733424000},"page":"72-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Patient journey and treatment patterns in adults with IPF based on health care data in Sweden from 2001 to 2015"],"prefix":"10.1016","volume":"155","author":[{"given":"C. Magnus","family":"Sk\u00f6ld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisen","family":"Arnheim-Dahlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5093-6980","authenticated-orcid":false,"given":"Christer","family":"Janson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Uwe","family":"Kirchgaessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3807-3315","authenticated-orcid":false,"given":"Giovanni","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.rmed.2019.06.001_bib1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.7326\/0003-4819-134-2-200101160-00015","article-title":"Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy","volume":"134","author":"Selman","year":"2001","journal-title":"Ann. Intern. Med."},{"issue":"7","key":"10.1016\/j.rmed.2019.06.001_bib2","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S2213-2600(14)70101-8","article-title":"Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11","volume":"2","author":"Raghu","year":"2014","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2019.06.001_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1183\/13993003.01653-2015","article-title":"Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18-64 years old","volume":"48","author":"Raghu","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"124","key":"10.1016\/j.rmed.2019.06.001_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1183\/09059180.00000812","article-title":"An earlier and more confident diagnosis of idiopathic pulmonary fibrosis","volume":"21","author":"du Bois","year":"2012","journal-title":"Eur. Respir. Rev."},{"issue":"4","key":"10.1016\/j.rmed.2019.06.001_bib5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"Ley","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2019.06.001_bib6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/joim.12571","article-title":"Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group","volume":"281","author":"Skold","year":"2017","journal-title":"J. Intern. Med."},{"issue":"2","key":"10.1016\/j.rmed.2019.06.001_bib7","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2019.06.001_bib8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/PPA.S37233","article-title":"Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis","volume":"8","author":"Takeda","year":"2014","journal-title":"Patient Prefer. Adherence"},{"issue":"5","key":"10.1016\/j.rmed.2019.06.001_bib9","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"9779","key":"10.1016\/j.rmed.2019.06.001_bib10","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.rmed.2019.06.001_bib11","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.rmed.2019.06.001_bib12","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 61","key":"10.1016\/j.rmed.2019.06.001_bib13","first-page":"OA3402","article-title":"Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON","volume":"50","author":"Crestani","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2019.06.001_bib14","doi-asserted-by":"crossref","first-page":"e000105","DOI":"10.1136\/bmjresp-2015-000105","article-title":"Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials","volume":"3","author":"Lancaster","year":"2016","journal-title":"BMJ Open Respir. Res."},{"key":"10.1016\/j.rmed.2019.06.001_bib15","author":"European Medicines Agency (EMA)"},{"key":"10.1016\/j.rmed.2019.06.001_bib16","author":"European Medicines Agency (EMA)"},{"issue":"6","key":"10.1016\/j.rmed.2019.06.001_bib17","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/resp.13024","article-title":"Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions","volume":"22","author":"Galli","year":"2017","journal-title":"Respirology"},{"issue":"9","key":"10.1016\/j.rmed.2019.06.001_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/jcm5090078","article-title":"Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis","volume":"5","author":"Hughes","year":"2016","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.rmed.2019.06.001_bib19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/MCP.0000000000000190","article-title":"Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis","volume":"21","author":"King","year":"2015","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.rmed.2019.06.001_bib20","author":"National Board of Health and Welfare (NBHW)"},{"key":"10.1016\/j.rmed.2019.06.001_bib21","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"issue":"8","key":"10.1016\/j.rmed.2019.06.001_bib22","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/pds.3465","article-title":"Validation of asthma and eczema in population-based Swedish drug and patient registers","volume":"22","author":"Ortqvist","year":"2013","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"2","key":"10.1016\/j.rmed.2019.06.001_bib23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/00365521.2016.1246605","article-title":"Validating inflammatory bowel disease (IBD) in the Swedish national patient register and the Swedish quality register for IBD (SWIBREG)","volume":"52","author":"Jakobsson","year":"2017","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.rmed.2019.06.001_bib24","author":"National Board of Health and Welfare (NBHW)"},{"issue":"9","key":"10.1016\/j.rmed.2019.06.001_bib25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur. J. Epidemiol."},{"issue":"6","key":"10.1016\/j.rmed.2019.06.001_bib26","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/joim.12067","article-title":"Combination of budesonide\/formoterol more effective than fluticasone\/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study","volume":"273","author":"Larsson","year":"2013","journal-title":"J. Intern. Med."},{"issue":"1","key":"10.1016\/j.rmed.2019.06.001_bib27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/03009734.2011.653015","article-title":"Automated data extraction--a feasible way to construct patient registers of primary care utilization","volume":"117","author":"Martinell","year":"2012","journal-title":"Ups. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.rmed.2019.06.001_bib28","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/09031936.00217614","article-title":"Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry","volume":"46","author":"Behr","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.rmed.2019.06.001_bib29","first-page":"103","article-title":"Risk factors of acute exacerbation of idiopathic pulmonary fibrosis","volume":"27","author":"Kondoh","year":"2010","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"5","key":"10.1016\/j.rmed.2019.06.001_bib30","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1183\/09031936.01.17509540","article-title":"Quality of life of idiopathic pulmonary fibrosis patients","volume":"17","author":"De Vries","year":"2001","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2019.06.001_bib31","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00084-2017","article-title":"mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis","volume":"3","author":"Rajala","year":"2017","journal-title":"ERJ Open Res."},{"issue":"135","key":"10.1016\/j.rmed.2019.06.001_bib32","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1183\/09059180.00011514","article-title":"Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis","volume":"24","author":"Cottin","year":"2015","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.rmed.2019.06.001_bib33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fmed.2017.00123","article-title":"Comorbid conditions in idiopathic pulmonary fibrosis: recognition and management","volume":"4","author":"Oldham","year":"2017","journal-title":"Front. Med."},{"issue":"4","key":"10.1016\/j.rmed.2019.06.001_bib34","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1183\/13993003.02316-2014","article-title":"Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"2 Pt 1","key":"10.1016\/j.rmed.2019.06.001_bib35","first-page":"646","article-title":"Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)","volume":"161","author":"American Thoracic Society","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"21","key":"10.1016\/j.rmed.2019.06.001_bib36","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Idiopathic Pulmonary Fibrosis Clinical Research","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.rmed.2019.06.001_bib37","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2019.06.001_bib38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40248-018-0126-7","article-title":"Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries","volume":"13","author":"Pesonen","year":"2018","journal-title":"Multidiscip. Respir. Med."},{"key":"10.1016\/j.rmed.2019.06.001_bib39","first-page":"A5351","article-title":"Pirfenidone and nintedanib compliance and persistence in a real world setting","volume":"195","author":"Lalla","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2019.06.001_bib40","doi-asserted-by":"crossref","first-page":"A441","DOI":"10.1016\/j.chest.2017.08.468","article-title":"Adherence and persistence to antifibrotic treatments for idiopathic pulmonary fibrosis","volume":"152","author":"Raimundo","year":"2017","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.rmed.2019.06.001_bib41","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00084-2018","article-title":"Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study","volume":"4","author":"Cottin","year":"2018","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.rmed.2019.06.001_bib42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fmed.2017.00213","article-title":"Longitudinal \"Real-World\" outcomes of pirfenidone in idiopathic pulmonary fibrosis in Greece","volume":"4","author":"Tzouvelekis","year":"2017","journal-title":"Front. Med."},{"issue":"8 Suppl 3","key":"10.1016\/j.rmed.2019.06.001_bib43","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/MLR.0b013e31829b1d2a","article-title":"Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases","volume":"51","author":"Raebel","year":"2013","journal-title":"Med. Care"},{"issue":"5","key":"10.1016\/j.rmed.2019.06.001_bib44","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N. Engl. J. Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119301829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119301829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:53:15Z","timestamp":1760615595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611119301829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":44,"alternative-id":["S0954611119301829"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2019.06.001","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient journey and treatment patterns in adults with IPF based on health care data in Sweden from 2001 to 2015","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2019.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}